Navigation Links
Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies

According to a study done by Kate Rittenhouse-Olson, Ph.D., the monoclonal antibody developed by researchers at the University at Buffalo has been shown to extend// significantly the survival of mice with human breast-cancer tumors.

The study also finds that the antibody inhibits the cancer's spread to the lungs in the animals by more than 50 percent. The results of this study were published in the November 2006 issue of Journal Neoplasia.

The antibody, named JAA-F11, targets a particular disaccharide, an antigen known as TF-Ag, which aids the adhesion and spread of certain cancer cells. While the antibody did not kill the cancer cells, it blocked stages of cancer-cell growth that allow the cells to adhere to organ tissue, the research showed.

Mice with breast-cancer tumors that received the antibody had a median survival time of 72 days, compared to 57 days for the animals that did not receive JAA-F11, the study found. In addition, exposing cultures of tumor cells to the antibody inhibited cell growth by a statistically significant 16 percent.

Kate Rittenhouse-Olson, Ph.D., associate professor of clinical and laboratory sciences in the UB School of Medicine and Biomedical Sciences, is senior author on the study.

"This antibody binds with a carbohydrate on the tumor cell surface that is involved in adhesion of the cell during the metastatic process," said Rittenhouse-Olson. "Not only would drugs attached to the antibody JAA-F11 bind to the tumor cell surface to direct their cytotoxic effect, but the binding of the antibody itself would block the cell from metastasizing."

The antibody was tested using in vitro models of tumor cell growth, in assays to determine its ability to damage or kill cells (cytotoxicity), in various models of cancer metastasis, and, finally, in mice with metastatic breast cancer.

"In addition to providing a survival advantage," said Rittenhouse-Olson, "JAA-F11 immunothera py reduced the metastatic tumor burden significantly, reflected by both a dramatic decline in the overall incidence of spontaneous metastasis to the lung -- 88 percent to 47 percent -- and fewer macroscopic metastatic lesions."

The research group currently is determining if JAA-F11 could increase the effectiveness of existing cancer drugs, she said, as well as studying the possibility of using the antibody as a vehicle for the targeted delivery of drugs to aid cancer diagnosis and therapy.

Jamie Heimburg and Jun Yan, co-first authors on the paper, were graduate students in Rittenhouse-Olson's lab at the time of the study.

Also contributing to the research were Susan Morey and Robert Klick, Ph.D., from the UB Department of Biotechnical and Clinical Laboratory Sciences; Linda Wild, M.D., from UB's Pathology Department; Olga V. Glinskii, M.D., Vladislav V. Glinsky, M.D., and Virginia H. Huxley, Ph.D., from the University of Missouri, and Rene Roy, Ph.D., from the University of Quebec in Montreal. Glinsky also is affiliated with the Harry S. Truman Memorial Veterans Hospital in Columbia, Mo.

The research was supported by grants from the National Institutes of Health to Rittenhouse-Olson, Glinskii and Huxley; from the VA Merit Review Program to Glinsky, and from the U.S. Department of Defense to Heimberg and Rittenhouse-Olson.

The University at Buffalo is a premier research-intensive public university, the largest and most comprehensive campus in the State University of New York. The School of Medicine and Biomedical Sciences is one of five schools that constitute UB's Academic Health Center.

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. Long-Term Survival can be Predicted by a Simple Lung Test
2. Hepatitis G May Boost HIV Survival
3. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
4. Longer Lung Cancer Survival
5. ICU Survival can be improved by Antibiotic use
6. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
7. Improving Survival Rate Of Lung Cancer Patients
8. Combination Therapy Effective In Improving Lung Cancer Survival
9. Symptoms Found To Be A Good Predictor Of Cancer Survival
10. Survival Of Colon Cancer Patients
11. Public Defibrillators Found To Improve Survival Rate
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... , ... December 05, 2016 , ... The new knee ... individual looking to buy neoprene knee sleeves for lifting and any sport ... focuses heavily on two main aspects to provide a higher quality knee sleeve performance. ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... called the CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial ... healthcare settings. , Over the last 60 years, studies have shown that ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... wins "Best Surgical Body Shaping" at the 2016 Anti-Aging & Beauty ... France. , The Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings ...
(Date:12/4/2016)... , ... December 04, 2016 , ... Responsible dental care ... must brush properly to achieve optimal results. This important necessity inspired an inventor from ... for a way to ensure that people break or avoid bad techniques of brushing ...
(Date:12/2/2016)... Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... lien basis to help personal injury victims find high quality medical care. When the ... Los Angeles area. Fast forward to present day and the now ten-page directory features ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology: